Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas (Study P04460)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00202891
Recruitment Status : Withdrawn (No further local interest in pursuing the study.)
First Posted : September 20, 2005
Last Update Posted : June 3, 2015
Fulford India Limited
Information provided by (Responsible Party):
Merck Sharp & Dohme LLC

Brief Summary:
This open-label, randomized, parallel-group clinical study is designed to compare the efficacy and safety of the topical antibiotic, sisomicin cream, with that of another topical antibiotic cream, nadifloxacin cream, in the treatment of Indian patients with primary pyodermas.

Condition or disease Intervention/treatment Phase
Pyoderma Drug: sisomicin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas
Study Start Date : May 2007
Actual Study Completion Date : September 2007

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients of either sex and suffering from primary pyodermas requiring topical antibiotic therapy without occlusive dressings.
  • >=6 years of age.
  • Written informed consent.

Exclusion Criteria:

  • Patients must not take any other antibiotics.
  • Patients should not be hypersensitive to any of the test drugs.
  • Patients are not to have any other investigational drug within one month of starting this study.
  • Patients cannot be enrolled more than once in the study.
  • Patients must not have any significant medical condition which, in the judgment of the investigator, might interfere with the study or require treatment.
  • Pregnant women and nursing mothers are to be excluded.
Layout table for additonal information
Responsible Party: Merck Sharp & Dohme LLC Identifier: NCT00202891    
Other Study ID Numbers: P04460
First Posted: September 20, 2005    Key Record Dates
Last Update Posted: June 3, 2015
Last Verified: June 2015
Keywords provided by Merck Sharp & Dohme LLC:
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action